Monday, December 30, 2019 3:45:59 PM
Quote from your post:
"Moreover, there is a chance that the current management team and board, which is impressive for a micro-cap, can create value by extending the use of their pumps for other emerging subcutaneous drugs. If I am right, the stock could have multiples of upsidefrom current levels"
Your post highlights a couple of things.
One, KRMD has an extremely talented and dedicated group(management and board) for a micro-cap. This is a team that can grow the company. The chairman of the board, John Fletcher, has made himself and others a lot of money by optimizing shareholder value!! (see link below)
Two, The potential for other, non plasma based drugs, going to subcutaneous infusions as the preferred manner of drug delivery is huge! Will this happen?? Who knows? The drivers to go to subcutaneous infusions remain the same. These include, cost savings, patient(or caretaker) convenience, and less toxicity do to drug level fluctuation in the body. It is a tantalizing thought to imagen that plasma based drug therapies are just the tip of the iceberg for subcutaneous infusions and KRMD.
https://www.businesswire.com/news/home/20190930005433/en/RMS-Medical-Products-Names-R.-John-Fletcher
Recent KRMD News
- KORU Medical Systems to Report First Quarter 2024 Financial Results on May 1, 2024 • Business Wire • 04/17/2024 11:00:00 AM
- KORU Medical Systems Announces Successful Appeal in EU Notified Body Review • Business Wire • 04/11/2024 08:05:00 PM
- KORU Medical Systems to Present Data Demonstrating 97% Adherence on Its Freedom Infusion System for Large Volume Subcutaneous Administration at NHIA 2024 Conference • Business Wire • 03/18/2024 09:24:00 PM
- KORU Medical Systems, Inc. Announces 2023 Fourth Quarter, Full Year Financial Results, and 2024 Guidance • Business Wire • 03/13/2024 08:05:00 PM
- KORU Medical Systems Announces a Feasibility Study to Enter Ambulatory Infusion Settings with a Commercialized Biologic • Business Wire • 03/11/2024 08:05:00 PM
- KORU Medical Systems Signs a Clinical Supply Agreement for Phase 3 Trial with Leading Pharma Partner Using Custom Device for a Novel Subcutaneous Immunoglobulin • Business Wire • 03/06/2024 12:00:00 PM
- KORU Medical Systems to Report Fourth Quarter and Full Year 2023 Financial Results on March 13, 2024 • Business Wire • 02/21/2024 12:00:00 PM
- KORU Medical Systems to Participate in Piper Sandler’s 35th Annual Healthcare Conference • Business Wire • 11/29/2023 12:00:00 PM
- KORU Medical Systems, Inc. to Host Investor Day on December 5, 2023 • Business Wire • 11/28/2023 01:00:00 PM
- KORU Medical Systems, Inc. Announces Development Agreement for Next-generation Subcutaneous Immunoglobulin Infusion System • Business Wire • 11/08/2023 09:10:00 PM
- KORU Medical Systems, Inc. Appoints Ken Miller as Chief Commercial Officer • Business Wire • 11/08/2023 09:08:00 PM
- KORU Medical Systems, Inc. Announces 2023 Third Quarter Financial Results and Updates Full Year 2023 Outlook • Business Wire • 11/08/2023 09:05:00 PM
- KORU Medical Systems, Inc. Receives FDA 510(k) Clearance for FREEDOM60® Infusion System With Hizentra® 50 ML Prefilled Syringes • Business Wire • 11/07/2023 09:05:00 PM
- KORU Medical Systems to Participate in Upcoming Investor Conferences • Business Wire • 11/02/2023 08:05:00 PM
- KORU Medical Systems to Report Third Quarter Financial Results on November 8, 2023 • Business Wire • 10/25/2023 08:05:00 PM
- KORU Medical Systems to Present Two Abstracts at the Immunoglobulin National Society 2023 National Conference • Business Wire • 10/05/2023 11:05:00 AM
- KORU Medical Systems, Inc. Announces Appointment of Edward Wholihan to Its Board of Directors • Business Wire • 10/04/2023 08:05:00 PM
- KORU Medical Systems to Participate in the Gilmartin Group Emerging Growth Company Showcase • Business Wire • 09/15/2023 12:05:00 PM
- KORU Medical Systems, Inc. Announces 2023 Second Quarter Financial Results and Updates Full Year 2023 Outlook • Business Wire • 08/09/2023 08:05:00 PM
- KORU Medical Systems to Participate in the Genuity 43rd Annual Growth Conference • Business Wire • 08/08/2023 08:05:00 PM
- KORU Medical Systems, Inc. Announces Preliminary Second Quarter 2023 Revenues and Provides Business, Outlook and Executive Updates • Business Wire • 08/02/2023 09:15:00 PM
- KORU Medical Systems to Report Second Quarter Financial Results on August 9, 2023 • Business Wire • 07/31/2023 08:05:00 PM
- KORU Medical Systems Announces Novel Therapies Collaboration for Late-Stage Endocrinological Biologic • Business Wire • 07/27/2023 08:05:00 PM
- KORU Medical Systems, Inc. Announces 510(K) Submission for Freedom60® Infusion System With Hizentra® 50 Ml Prefilled Syringes • Business Wire • 07/10/2023 11:01:00 AM
- KORU Medical Systems, Inc. Names Andrew LaFrence as Chief Financial Officer • Business Wire • 06/27/2023 11:05:00 AM
Coinllectibles' Subsidiary, Grand Town Development Limited, Acquires Rare Song Dynasty Ceramics Worth Over USD28million • COSG • Apr 18, 2024 8:03 AM
ILUS Provides Form 10-K Filing Update • ILUS • Apr 17, 2024 9:54 AM
Glucotrack Announces Expansion of Its Continuous Glucose Monitoring Technology to Epidural Glucose Monitoring • GCTK • Apr 17, 2024 8:00 AM
Maybacks Global Entertainment To Fire Up 24 New Stations in Louisiana • AHRO • Apr 16, 2024 1:30 PM
Cannabix Technologies Begins Certification of Contactless Alcohol Breathalyzer, Re-Brands product series to Breath Logix • BLOZF • Apr 16, 2024 8:52 AM
Kona Gold Beverages, Inc. Acquires Surge Distribution LLC from Loud Beverage Group, Inc. (LBEV) • KGKG • Apr 16, 2024 8:30 AM